Venture Visionary Partners LLC Sells 5,629 Shares of GSK PLC Sponsored ADR $GSK

Venture Visionary Partners LLC lessened its position in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 50.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,603 shares of the pharmaceutical company’s stock after selling 5,629 shares during the quarter. Venture Visionary Partners LLC’s holdings in GSK were worth $217,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Kingsview Wealth Management LLC boosted its holdings in shares of GSK by 1.8% in the 1st quarter. Kingsview Wealth Management LLC now owns 15,227 shares of the pharmaceutical company’s stock valued at $590,000 after acquiring an additional 271 shares during the last quarter. Rehmann Capital Advisory Group boosted its holdings in GSK by 4.6% during the first quarter. Rehmann Capital Advisory Group now owns 6,407 shares of the pharmaceutical company’s stock worth $248,000 after buying an additional 279 shares in the last quarter. First PREMIER Bank boosted its holdings in GSK by 6.5% during the first quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company’s stock worth $181,000 after buying an additional 286 shares in the last quarter. Northwest Bank & Trust Co boosted its holdings in GSK by 1.3% during the fourth quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company’s stock worth $765,000 after buying an additional 289 shares in the last quarter. Finally, OneAscent Financial Services LLC boosted its holdings in GSK by 3.9% during the first quarter. OneAscent Financial Services LLC now owns 7,700 shares of the pharmaceutical company’s stock worth $297,000 after buying an additional 292 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Price Performance

Shares of NYSE GSK opened at $40.0450 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $44.67. The firm has a 50-day simple moving average of $38.35 and a 200-day simple moving average of $38.08. The stock has a market capitalization of $81.60 billion, a price-to-earnings ratio of 18.54, a price-to-earnings-growth ratio of 1.74 and a beta of 0.51.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm had revenue of $10.64 billion during the quarter, compared to analyst estimates of $7.92 billion. During the same quarter in the prior year, the firm posted $0.43 earnings per share. GSK’s quarterly revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, equities analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be issued a $0.4206 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.2%. GSK’s dividend payout ratio is currently 77.78%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Hsbc Global Res raised shares of GSK to a “strong sell” rating in a report on Monday, April 28th. Wall Street Zen upgraded shares of GSK from a “hold” rating to a “buy” rating in a research report on Sunday, August 3rd. Finally, Berenberg Bank restated a “hold” rating on shares of GSK in a research report on Tuesday, June 3rd. Seven investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, GSK has a consensus rating of “Reduce” and a consensus price target of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.